- This topic has 34 replies, 4 voices, and was last updated 1 year, 2 months ago by
.
- Posts
January 9 – 15 2022 FEAR NOT Brave Investors Where have we been and where are we going? Join our weekly market thread on Traders Community… Well, Hell
[See the full post at: Traders Market Weekly: Rates, Banks and Herd Mentality]Greetings from the cold DEER-infested mtns. of SW VA
DOW is off about 400 points as the great SANTA rally has run out of steam
Folks will only pay so much for DUTCH TULIPS in greatest PONZI scheme in history
and even BUILD BACK BRANDON (lol) — won’t save the world 😉 🙂The futures market has come down from prior highs in front of Fed Chair Powell’s confirmation hearing, which starts at 10:00 a.m. ET. The S&P 500 futures currently trade six points, or 0.1%, above fair value.
There’s been a ton of guidance and ratings changes this morning, but they haven’t a noticeable impact on the broader market. Investors will be tuning in to Mr. Powell’s hearing for any commentary on policy normalization.
The 2-yr yield is up four basis points to 0.94% on expectations for a more aggressive Fed, while the 10-yr yield is unchanged at 1.77% after trading at 1.74% overnight. The uptick in the latter has pressured the rebound attempt in the futures market.
Major European indices trade higher across the board. European Central Bank Chief Economist Lane repeated the view that inflation will slow later in 2022, slipping back below the 2.0% target at the end of the current forecast period. Nokia increased its margin guidance for the year.
STOXX Europe 600: +0.9%
Germany’s DAX: +1.1%
U.K.’s FTSE 100: +0.6%
France’s CAC 40: +1.0%
Italy’s FTSE MIB: +0.8%
Spain’s IBEX 35: +0.5%CVS Health (CVS 106.39, +1.33): +1.3% after raising its FY21 EPS guidance above consensus.
Illumina (ILMN )378.00, +15.72): +4.3% after guiding Q4 and FY22 revenue above consensus and announcing multiple new partnerships.
IBM (IBM 132.00, -3.03): -2.2% after the stock was downgraded to Sell from Neutral at UBS.
Abercrombie & Fitch (ANF 34.15, +1.80): +5.6% even though the company lowered its fiscal Q4 revenue guidance.
Big Lots (BIG 42.90, -3.44): -7.4% after guiding fiscal Q4 EPS below consensus.Equity indices in the Asia-Pacific region ended Tuesday on a mostly lower note. Japan’s Nikkei: -0.9% Hong Kong’s Hang Seng: UNCH China’s Shanghai Composite: -0.7% India’s Sensex: +0.4% South Korea’s Kospi: +0.4% Australia’s ASX All Ordinaries: -0.7%.
Positive bias carries over from yesterday’s comeback effort
Long-term interest rates remain calm
Fed Chair Powell confirmation hearing starts at 10:00 a.m. ET
CVS, ILMN upside guidance; ANF, BIG downside guidance
Rating changes for IBM, VZ, INTC, TMUS, AALS&P Futures vs Fair Value: +22.0
10 yr Note: 1.753%
USD/JPY: 115.40 +0.22
EUR/USD: 1.1327 -0.0001
Europe: FTSE: +0.6% DAX: +1.2% CAC: +1.4%
Asia: Hang Seng: 0.0% Shanghai: -0.7% Nikkei: -0.9%
Gold (1805.20 +6.40) Silver (22.55 +0.9) Crude (79.43 +1.20)Dow 36,252.02 183.15 0.51%
S&P 500 4,713.07 42.78 0.92%
Nasdaq 15,153.45 210.62 1.41%
GlobalDow 4,260.25 38.03 0.90%
Gold 1,822.50 23.70 1.32%
Oil 81.49 3.26 4.17%Never wind, nor snow, nor darkness of night or even 7% INFLATION
will keep pit traders from bidding up these markets higher as
BAD NEWS on main street = Good news on WALL & “K” streets 😉The WALL STREET BULLS are celebrating deep in the heart of TEXAS – lol 🙂
And in “420” type news — Devil weed can now stop COVID .. you can’t make this stuff up – lol 🙂
https://fortune.com/2022/01/12/cannabis-compounds-stop-covid-virus-infecting-human-cells-lab-study/
Cannabis compounds prevented the virus that causes COVID-19 from penetrating healthy human cells, according to a laboratory study published in the Journal of Nature Products.
The two compounds commonly found in hemp — called cannabigerolic acid, or CBGA, and cannabidiolic acid, or CBDA — were identified during a chemical screening effort as having potential to combat coronavirus, researchers from Oregon State University said. In the study, they bound to spike proteins found on the virus and blocked a step the pathogen uses to infect people.
The researchers tested the compounds’ effect against alpha and beta variants of the virus in a laboratory. The study didn’t involve giving the supplements to people or comparing infection rates in those who use the compounds to those who don’t.
- You must be logged in to reply to this topic.